These findings provide the first evidence that the effects of ER ligands in endothelial HAECs and prostate cancer cells could be dissociated and support the feasibility for the development of a novel therapeutic agent for anti-androgen therapy of prostate cancer with minimal cardiovascular side-effects. This evidence concerns the gene ESR1 and Familial prostate cancer.